| | |
| Clinical data | |
|---|---|
| Trade names | Duranest |
| AHFS/Drugs.com | Micromedex Detailed Consumer Information |
| MedlinePlus | a603026 |
| Pregnancy category |
|
| Routes of administration | Parenteral |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | n/a |
| Metabolism | Hepatic |
| Elimination half-life | 2.5 hours |
| Excretion | Renal |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.048.296 |
| Chemical and physical data | |
| Formula | C17H28N2O |
| Molar mass | 276.424 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| | |
Etidocaine, marketed under the trade name Duranest, is an amide-type local anesthetic given by injection during surgical procedures and labor and delivery. Etidocaine has a long duration of activity, and the main disadvantage of use during dentistry is increased bleeding during surgery. [1]
The amide reaction between 2,6-xylidine (1) and 2-bromobutyryl chloride [22118-12-3] (2) gives 2-Bromo-N-(2,6-Dimethylphenyl)Butanamide [53984-81-9] (3). Alkylation with N-Ethylpropylamine [20193-20-8] (4) gives Etidocaine (5).